SecBot SecBot
424B5 ·Filed May 5, 2026

IDYA

IDEAYA Biosciences, Inc.
MIXED
Impact 5/10
Horizondays Processed6mo ago SEC0001193125-26-206788
Notable filing: 424B5
Actionable Insight ◆ Mixed

Monitor the pace of ATM sales and any use-of-proceeds announcements. The offering may create near-term downward pressure due to dilution, but the strong cash position and positive clinical data provide a floor. Watch for potential acceleration of sales if the stock remains elevated post-earnings.

DirectionMixed
Confidencehigh
Horizondays

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$28.74
T+0 close · May 5, 2026 · via day close
Latest settled
+23.52%
T+60 · $35.50
Vs SPY
+21.46%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 6 $28.74entry
  2. T+1 · 6mo ago −1.74%α −1.41% · $28.24
  3. T+5 · 6mo ago −2.16%α −3.29% · $28.12
  4. T+20 · 6mo ago −1.18%α −3.96% · $28.40
  5. T+60 · 4mo ago +23.52%α +21.46% · $35.50

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

IDEAYA Biosciences filed a prospectus supplement on May 5, 2026, for an at-the-market (ATM) offering of up to $156.6 million in common stock, the remaining portion of a $350 million facility established in January 2024. The filing coincides with the same day's positive earnings release and clinical trial results. The offering is dilutive (~6.3% of market cap) but the company's strong cash position ($973M) and positive pipeline momentum may offset some negative sentiment.

Key Facts

  • Up to $156,552,996.81 in common stock remains available under the ATM facility (already sold $193,447,003.19)
  • Stock price as of May 1, 2026: $28.19 per share
  • Net tangible book value per share as of March 31, 2026: $10.67; dilution of $16.52 per share to new investors
  • Company had ~$973 million in cash, cash equivalents, and marketable securities as of March 31, 2026
  • Commission to Jefferies: up to 3.0% of gross proceeds
  • Positive Phase 2/3 OptimUM-02 trial results announced on April 13, 2026, met primary endpoint
  • Proceeds for general corporate purposes, including clinical development and potential commercialization

Financial Impact

Dilution of approximately $16.52 per share on the assumed $28.19 offering price; offering size ~6.3% of market cap

dilutionshare countbook value

Risk Factors

  • Continued dilution from ongoing ATM sales
  • Potential overhang from future equity issuances
  • Execution risk in commercialization with raised capital

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
88% bullish (25 analysts)

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
424B5 Filing (Primary)0001193125-26-206788
Document: d30692dexfilingfees.htm0001193125-26-206788
Document: 0001193125-26-206788-index-headers.html0001193125-26-206788
Document: 0001193125-26-206788-index.html0001193125-26-206788
Document: 0001193125-26-206788.txt0001193125-26-206788

Track record

13 reports on IDYA

Performance horizon

2 of 5 bullish or bearish reports moved the stock their way by T+5. Best: +15.66% at T+60 after the Apr 13, 2026 report. 3 of 5 went positive at some point.

Filters
  1. Nov 3, 202613d ago Institutional Cluster Neutral 3/10 Entry $31.33 to $31.75 Now $30.36 −3.10% ▲ +1.34% +1.93% vs SPY
  2. Nov 3, 202613d ago 8-K Neutral 5/10 Entry $31.33 to $31.75 Now $30.36 −3.10% ▲ +1.34% +1.93% vs SPY
  3. Oct 6, 20265w ago 144 Bearish 6/10 Entry $36.26 to $33.86 Now $30.36 +16.27% ▲ +6.62% +5.64% vs SPY
  4. Aug 4, 202614w ago 8-K Neutral 4/10 Entry $36.11 to $36.84 Now $30.36 −15.92% ▲ +2.02% +2.12% vs SPY
  5. Jun 23, 202620w ago 8-K Neutral 2/10 Entry $36.28 to $36.17 Now $30.36 −16.32% ▼ −0.30% −2.01% vs SPY
  6. Jun 10, 202622w ago 8-K Bearish 6/10 Entry $28.84 to $31.26 Now $30.36 −5.27% ▼ −8.39% −7.96% vs SPY
  7. Jun 9, 202622w ago 424B5 Bearish 6/10 Entry $27.60 to $30.57 Now $30.36 −10.00% ▼ −10.76% −7.33% vs SPY
  8. Jun 8, 202623w ago 424B5 Bearish 6/10 Entry $28.07 to $30.23 Now $30.36 −8.16% ▼ −7.70% −5.28% vs SPY
  9. Jun 3, 202623w ago 8-K Neutral 4/10 Entry $28.40 to $27.60 Now $30.36 +6.90% ▼ −2.82% +1.00% vs SPY
  10. May 5, 202627w ago 8-K Neutral 2/10 Entry $28.74 to $28.12 Now $30.36 +5.64% ▼ −2.16% −3.29% vs SPY
Showing 10 of 13

US Market Status

Market Closed · Opens Wed (10h 40m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 5, 2026